The blood pressure-lowering effect of dairy products holds the potential to decrease the risk of cardiovascular disease (CVD). An open question is if the successful expression of functional properties of the probiotic strain depends on host biomarkers and/or food matrix properties. The probiotic Lactobacillus plantarum strain TENSIA® (DSM 21380) is a novel microorganism with antimicrobial and antihypertensive functional properties. The aim of this study was to characterise the functional properties of the probiotic L. plantarum TENSIA and compare its effects on host anthropometric, clinical, and blood biomarkers when consumed with cheese or yoghurt. This study involved two double-blinded randomised placebo-controlled exploratory trials (ISRCTN15061552 and ISRCTN79645828) of healthy adults over a three-week period. The three-week consumption of probiotic L. plantarum TENSIA in a daily dose of 1×10 10 cfu in probiotic cheese or a daily dose of 6×10 9 cfu in yoghurt with different content of carbohydrates, proteins, and lipids did not significantly change the body mass index (BMI), plasma glucose and lipid levels, or inflammatory markers in the blood. Reduced lowered systolic and diastolic blood pressure values were detected, regardless of food matrix or baseline values for blood pressure and BMI. In conclusion, our study showed that three-week consumption of the probiotic L. plantarum TENSIA either in cheese or yoghurt lowered diastolic and systolic blood pressure regardless of food matrix and baseline values of blood pressure and BMI, confirming the impact of the functional properties of the probiotic strain in decreasing CVD risk.
Introduction
A substantial body of evidence has suggested that dietary approaches are becoming more relevant for prevention of metabolic syndrome, including hypercholesterolaemia, glucose tolerance, and elevated blood pressure (BP) (Appel, 2009; Shirani et al., 2013) . A high consumption of milk and dairy products has shown a lowering effect on cardiovascular disease risk, according to a systematic review and meta-analysis (Elwood et al., 2008) . Moreover, the consumption of dairy products has been associated with differences in the prevalence of metabolic syndrome, obesity, and high BP in special populations (Alvarez-Leon et al., 2006; Beydoun et al., 2008) . In contrast, however, among a representative sample of British adults, total dairy intake and specific dairy subgroups (high-or low-fat content, fermented dairy products) were not related to BP after adjustment for confounding factors (Heraclides et al., 2012) . Apparent differences in genetic variants of loci that contain genes known or suspected to be involved in regulation of BP may be the reason (Ehret et al., 2011) .
Some reports indicate that consuming a high-fat diet (including cheese) may promote obesity with low-grade inflammation (Cani and Delzenne, 2009) , which contributes to the development of atherosclerosis (Libby, 2002) . One of the possibilities for compensating for these effects may be functional foods containing pre-and probiotics (Nakamura and Omaye, 2012) . For instance, yoghurts and cheeses enriched with different prebiotic substances and beneficial probiotic bacteria are used worldwide to influence human health (Kumar et al., 2012) . In addition, in animal models, a decrease in fat storage with probiotic bacteria has been demonstrated (Aronsson et al., 2010; Beydoun et al., 2008) .
Impact of probiotic
Probiotic bacteria have the potential for temporal colonisation of the gut when consumed, supporting the competitive exclusion of pathogens directly or influencing the immune system; furthermore, they might modulate the composition and functional activity of microbiota in beneficial ways. Studies in humans and experimental animals have shown that not only can functional food change the metabolic profile of microbiota but it also can improve host metabolism, according to biomarkers of health that have been examined (McNulty et al., 2011) .
What remains unexamined is if the impact of probiotics on health indices depends on the delivery form of the probiotic or on individual variation of anthropometric, clinical, and laboratory data. Some evidence suggests that food matrices play an important role in the beneficial health effects of probiotics on the host, leading to recommendations that research focus on how the food matrix and dietary content interact with the most efficient probiotic strains (Isolauri, 2007; Isolauri et al., 2004) .
Cheese offers a food-based delivery vehicle for probiotic cultures and biogenic substances, such as conjugated linoleic acid and bioactive peptides, while in yoghurts the conversion of lactose into lactic acid lowers the pH and consequently favours the precipitation of milk proteins. The probiotic strain Lactobacillus plantarum TENSIA (DSM 21380) is a novel microorganism with antimicrobial and antihypertensive properties (Mikelsaar et al., 2012; Songisepp et al., 2012a) . The technology for its incorporation into cheese (Rätsep et al., 2009; Songisepp et al., 2012b) and yoghurt has been described and offers the possibility of comparing the effect of the two dairy products with different structures and lipid contents on indices of health in the general adult population.
The aim of this report was to assess some functional properties of L. plantarum TENSIA, such as angiotensin-1-converting enzyme (ACE) inhibitory activity and production of nitric oxide (NO) in vitro. Furthermore, we aimed to evaluate the impact of the probiotic strain L. plantarum TENSIA on anthropometric, clinical, and biochemical indices in healthy adults in two double-blinded randomised, placebo-controlled exploratory trials (ISRCTN15061552 and ISRCTN79645828) with dairy products of different food structure and content.
Material and methods
A novel probiotic strain L. plantarum TENSIA® was previously isolated from the gastrointestinal tract of a healthy Estonian child (Mikelsaar et al., 2002) . The strain L. plantarum TENSIA has been deposited in DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) under registration number DSM 21380. Molecular identification of the strain as L. plantarum was confirmed by internally transcribed spacer polymerase chain reaction and 16S rRNA sequencing (Songisepp et al., 2012a) . The functional properties and health effects of the strain have been patented (Songisepp et al., 2012a) .
Possible mechanisms of action of Lactobacillus plantarum TENSIA in vitro L. plantarum TENSIA was inoculated (2%, v/v) to 50 ml of pasteurised cow milk. Inoculation was carried out under sterile conditions, and the milk was kept for fermentation at 37 °C for 24 h. The experiment was repeated twice in parallel. To evaluate the ACE inhibitory activity of the milk during fermentation, the whey fraction was used, having been obtained as follows. The milk pH was adjusted to 3.4 by addition of 50% lactic acid. The milk acidified with the lactic acid and the milk fermented by L. plantarum TENSIA both were centrifuged at 6,000×g for 10 min; 10 N NaOH was added to the supernatants to increase the pH to 8.3, and the supernatant was then centrifuged at 6,000×g for 10 min. The milk hydrolysates were centrifuged at 6,000×g for 10 min. The supernatant was ultrafiltered through a 10-kDa cut-off filter (Millipore, Billerica, MA, USA) and in a second step of fractionation through a 3-kDa cut-off filter by centrifugation (4,000×g for 40 min at 15 °C). The final supernatant used for the study does not contain other compounds influencing ACE inhibition (Praveesh et al., 2011) .
The molar concentration of peptides in the supernatant was determined using a quantitative ninhydrin (Sigma-Aldrich, St. Louis, MO, USA) assay, a rapid and sensitive method for the quantitative determination of free amino groups. The technique involves the reaction of the free amine with ninhydrin under carefully controlled conditions and the determination of the resulting chromophore concentration in solution at 570 nm (Sarin et al., 1981) . Leucine (SigmaAldrich) was used as the standard for creating a standard curve.
The K-Assay® ACE Inhibition Screening Kit (Kamiya Biomedical Company, Seattle, WA, USA) was used for measurement of ACE inhibitory activity. The substrate for ACE was 3-hydroxybutyryl-Gly-Gly-Gly (3HB-GGG), and the amount of cleaved 3-hydroxybutyric acid (3HB) from 3HB-GGG was measured using the enzymatic method.
The inhibition activity was calculated with the following equation:
where blank1 is positive control (without ACE inhibition) and blank2 is the reagent blank. Each sample was assayed in triplicate. For determination of IC 50 (the concentration of an inhibitor required to inhibit 50% of the ACE activity), an inhibition curve was prepared with the sample concentration on the x axis and ACE inhibitory activity on the y axis.
Measurement of nitrogen mono-oxide production by L. plantarum TENSIA was carried out with 24-h old intact cells in 500 µl of MRS broth (Oxoid, Basingstoke, UK) or in 10 ml of MRS broth containing 3 or 30 mg of NaNO 3 with Apollo 4000 free radical analyser (WPI, Berlin, Germany) and electrodes of type. ISO-NOP electrode signals were registered for 5-7 min and the mean signal strength calculated. Each experimental point was measured in four independent parallels, and each parallel was measured twice. NO concentration was calculated according to standard curve correlation with the strength of the electrode signal.
Possible mechanisms of action of Lactobacillus plantarum TENSIA in vivo
The probiotic cheese Südamejuust Harmony™, containing L. plantarum TENSIA, was developed by E-Piim Production (Järva-Jaani, Estonia). The cheese production has been described in detail elsewhere (Songisepp et al., 2012a) . In brief, semi-hard Edam-type cheeses (fat content 26%) (control and probiotic) were prepared from cow milk with 0.8-1% of the pre-cultured cheese starter C92 (CSK Food Enrichment, Leeuwarden, the Netherlands). In probiotic cheese, the L. plantarum strain TENSIA was an adjunct starter.
The probiotic yoghurt was developed from adjusted and pasteurised (92-95 °C, 5 min) cow milk (fat content 4.7%) using L. plantarum TENSIA (2×10 11 cfu/g) as an adjunct starter (inoculation dose 1 g/t). In brief, the pasteurised milk was cooled to 35-43 °C before mixing with commercial starter cultures (Chr. Hansen, Hørsholm, Denmark) and the probiotic strain. The milk was fermented to pH 4.2-4.5 and cooled to 23-27 °C. The yoghurt was sweetened with 5% of sugar, packaged in plastic cups, and cooled to 2-6 °C. Control was similar yoghurt without the probiotic adjunct.
The human trials were performed according to the guidelines of the Declaration of Helsinki and consisted of two double-blind placebo-controlled cross-over trials. Both trials were approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (protocol numbers 184/T-10 from 2009; 190T-11 from 2010). All participants signed the written informed consent at enrolment and were given the option to withdraw from the study at any time.
Study TE4 (ISRCTN15061552) was performed to investigate the effect of semi-hard Edam-type cheese comprising L. plantarum TENSIA on health biomarkers in healthy adults (n=82). Within one month prior to the study, the participants were asked to continue their normal diet but to avoid probiotic products (e.g. food supplements, cheese, yoghurts, kefir, etc.). The trial started with three-week consumption of probiotic cheese, i.e. cheese containing L. plantarum TENSIA, or control cheese (50 g daily).
Study JOG2 (ISRCTN79645828) was performed to investigate the effect of yoghurt containing L. plantarum TENSIA on health biomarkers in healthy adults (n=43). Within one month prior to the study, participants were asked to continue their normal diet but to avoid probiotic products (e.g. food supplements, yoghurts, cheese, kefir, etc.). The trial started with three-week consumption of test yoghurt, i.e. yoghurt containing L. plantarum TENSIA, or control yoghurt (150 g daily).
In both trials, after a two-week washout period, volunteers were crossed over to another three-week period of consumption of the probiotic cheese or yoghurt, or control cheese and yoghurt. Participants underwent clinical examination, and plasma samples were collected after an overnight fast and abstinence from any medications, tobacco, alcohol, and tea or coffee. Each participant was evaluated for anthropometric indices. Body mass index (BMI) was calculated as the weight (kg) divided by squared height (m 2 ) and used to classify participants as being in the normal weight range (18.5-24.9 kg/m 2 ), overweight (≥25.0-29.9 kg/m 2 ), or obese (≥30.0 kg/m 2 ) (WHO, 2006) . Samples of fasting blood were collected four times: at recruitment, after administration of either the L. plantarum TENSIA-containing product or control product, after the washout period, and after the administration of the control or probiotic product at the end of the trial. Haematological indices (haemoglobin, erythrocytes, leukocytes, and lymphocytes; data not shown), inflammatory indices (white blood cell count, high-sensitivity C-reactive protein), and metabolic indices (plasma glucose and lipids: total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides) were determined using standard laboratory methods with certified assays in the local clinical laboratory (United Laboratories of Tartu University Clinics, Tartu, Estonia). Intervals for routine laboratory tests proposed by the Nordic Reference Interval Project (NORIP, www. furst.no/norip) were used as a reference. BP measurements were done using a mercury sphygmomanometer (Riester No 1002 DIPLOMAT presameter, Rudolf Riester GmbH, Jungingen, Germany). Participants were instructed to avoid any strenuous exercise and stimulants (alcohol, caffeine) for at least 24 h prior to any BP measurement and refrain from cold exposure, food, and fluid intake as well as smoking for at least 1 h prior to any BP measurement.
All measurements were done at the same individual time of day per person and within 07:00 and 13:00 for all participants by a properly trained nurse of the Tartu University Clinics. The BP of the volunteers was measured according to European Society of Hypertension (ESH) and the European Society of Cardiology guideline (Mancia et al., 2007) suggestions, i.e. each person was allowed to sit for ca. 10-15 min in a quiet temperature-controlled room (22 °C) before beginning the BP measurements. Peripheral BP was measured in both arms twice (2-3 min between two measurements), and the mean values were calculated.
Statistical analysis
Statistical analysis was performed by using R 2.10.1 (www.r-project.org) and GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). All data were expressed as mean and standard deviation. Baseline and intervention data were compared by paired t-tests or the Wilcoxon rank sum test according to the distribution of data. Furthermore, sex and the frequency of BMI category, systolic BP category, and number of smokers were compared between trials by the Chi-square test. The presence of correlation between variables was explored using Spearman's correlation. Differences were considered statistically significant if the P values <0.05.
Results

Functional properties of Lactobacillus plantarum TENSIA
In the in vitro analysis, the ACE inhibition curves of TENSIA and control milk with cleaved 3HB as the product differed significantly (P<0.05) (Figure 1 ). Between the two types of milk screened for ACE inhibitory activity, the control milk (acidified with lactic acid) showed a maximum inhibition percentage of 82.8% while milk fermented with TENSIA showed a maximum ACE inhibition of 83.6%. Overall, ACE inhibitory activity was significantly higher (P<0.05) for milk fermented with TENSIA, as indicated by the lower IC 50 of 2.7±0.9 µM compared to that for the control milk at 6.6±0.3 µM. L. plantarum TENSIA could produce NO in both MRS and skim milk and use NaNO 3 as a substrate for NO production. The amount of produced NO was related to substrate concentration (Table 1) .
Results of clinical trials
We assessed the effect of consumption of probiotic L. plantarum TENSIA cheese and yoghurt products separately in two different trials. The characteristics of probiotic cheese and yoghurt are given in Table 2 .
In trial TE4, the number of volunteers was almost twice that of trial JOG2, although the sex, age, and smoker distribution did not differ (Table 3) . However, they did differ significantly in BMI values (25.4 vs. 23.8 kg/m 2 , P=0.009), with cheese consumers having a higher BMI. In addition, the distribution of participants according to BMI category (<25 and ≥25 kg/m 2 ) differed between the two trials. Most of the yoghurt consumers fell into the BMI<25 kg/m 2 group while the cheese consumers were equally distributed between the higher and lower values of 25 kg/m 2 (P=0.029).
Both systolic and diastolic baseline BP values of participants in the cheese and yoghurt trials differed significantly (129.8 vs. 119.1 mmHg, P=0.001; and 83.6 vs. 77.0 mmHg, P=0.001, respectively) ( Table 3 ). The prevalence of individuals with different systolic BP values was evenly distributed in the cheese trial whereas in the yoghurt trial, the optimal and 127.9±10.9 mm Hg, P=0.0006). BP reduction was greater among persons with lower BMI (BMI<25 kg/m 2 ) in both trials while among participants with higher BMI (≥25 kg/ m 2 ), the BP reduction was seen only in the cheese trial (Table 5) .
We evaluated the relationships between changes in systolic BP with diastolic BP, BMI, glucose, cholesterol, LDLcholesterol, HDL-cholesterol, and triglyceride values during the probiotic period in both trials. Changes in BMI were significantly related to changes in systolic BP in the cheese trial (r=0.276, P=0.013), and reduced cholesterol levels were associated with changes in systolic BP (r=0.311, P=0.045) in the yoghurt trial. A negative correlation between reduced systolic BP and increased blood glucose was found among yoghurt consumers (r=-0.353, P=0.022) ( Table 6 ).
Impact of probiotic food on biomarkers
The two probiotic products differed in their structure and protein, carbohydrate, and fat content ( Table 2 ). The biggest difference was detected for carbohydrate (16 times in favour of yoghurt) and protein and fat (2.6 times and 2.0 times in favour of cheese, respectively) daily intake. At the same time, the intake of the probiotic strain TENSIA was quite similar. The energy load from cheese was higher than from yoghurt (175 kcal and 148.6 kcal, respectively).
The biochemical blood indices of the two groups of cheese and yoghurt consumers were quite stable. Remarkably, lowered values of blood LDL were found in consumers of both probiotic and control yoghurt (Table 7) . No differences were detected comparing the erythrocytes, platelets, and lymphocyte values (data not shown) or in the content of glucose and total cholesterol, HDL-cholesterol, and triglycerides either at baseline or after probiotic consumption (Table 7) . Thus, the highly different (16×) content of carbohydrates did not influence blood glucose 1 BL1 = baseline 1, at the recruitment; PRO = after probiotic treatment; BL2 = baseline 2, after washout; PL = after control treatment; BMI = body mass index; WBC = white blood cells; hs-CRP = high-sensitivity C-reactive protein. 
Discussion
The functional properties of the probiotic strain L. plantarum TENSIA exhibiting in vitro ACE inhibitory activity and NO production are the putative mechanisms responsible for lowering BP. We found an increased ACE inhibition in milk fermented with L. plantarum TENSIA in vitro, which indicated a possible mechanism for lowering systolic and diastolic BP. According to earlier studies, milk bioactive peptides may act as ACE inhibitors, thus inhibiting the renin-angiotensin system with consequent vasodilatation (Jauhiainen et al., 2005; Turpeinen et al., 2012) . Recently, Gupta et al. (2013) found ACE inhibitory activity in cheddar cheese. The strongest ACE inhibitors known to be produced by lactobacilli are rich of proline (i.e. Ile-Pro-Pro and Val-Pro-Pro), which makes them resistant to digestive peptidases. Moreover, besides single amino acids, also di-and tripeptides are absorbed in the intestine and thus the short peptides generated by lactobacilli may reach the host's bloodstream (De Leo et al., 2009) .
NO is a signalling molecule regulating a variety of biological functions. In the gastrointestinal tract it is synthesised by and sensed as a signal in the endothelial cells of local blood vessels, in tissue macrophages as well as in intestinal epithelial cells. Lactobacilli are suggested to induce NO synthase activity in host cells (Korhonen et al., 2001 (Korhonen et al., , 2002 Hu et al., 2013) and some of them are capable of producing NO by themselves (Xu and Verstraete, 2001) . Gaseous signalling molecules like NO, CO or H 2 S easily penetrate biological barriers and the signalling distance for NO is mainly limited by its short half-life, which allows covering distances up to a few hundred μm (Arzumanian et al., 2003) . However, it has recently been recognised that nitrite formation from NO is not an irreversible process, and via nitrite conversion NO signalling may reach systemic range (Lundberg et al., 2008) . For instance, NO and nitrite formation has been suggested to be the key mechanism of how oral microbiota reduce host's blood pressure (Kapil et al. 2013) .
Our results show production of NO by L. plantarum TENSIA in all growth media used, with a higher production in nitrate-rich environments, suggesting that nitrate is the preferred source for NO generation. NO synthesis was higher and depended more on nitrate concentration in MRS broth than in skim milk-based growth media implying that the NO generation is not only regulated by substrate availability, but a more complex interaction between the bacteria and its environment. Xu and Verstraete (2001) , who found only nitrate-derived NO production in lactobacilli, carried the experiments out in MRS broth only. Considering other previous reports (Iarullina et al., 2006; Morita et al., 1997) and differences between MRS broth and skim milk media observed by us, it cannot be excluded that non-nitrate sources, such as arginine, can under certain conditions also be used by TENSIA for NO generation. Nevertheless, although the mechanism needs additional clarification, NO production by TENSIA in gastrointestinal tract would be plausible. This could lead to increased levels of NO and/or nitrite in the intestinal tissue and a potential reason for decreased blood pressure. Of course, there also remains the possibility that TENSIA is inducing NO generation in host cells independently of its own NO production capability and the latter has no significant effect on blood pressure.
In two double-blind, placebo-controlled cross-over trials, we compared the effect of the probiotic strain TENSIA in different food carriers (cheese, yoghurt) on anthropometric, BP, and blood biomarkers of health in healthy adults. The main effect of the consumption of probiotic cheese and yoghurt was a decreased diastolic BP, while consuming probiotic cheese was linked to a significant reduction in systolic BP. Usually, both the amount and type of carbohydrate affect BP, and partial substitution of carbohydrate with either protein or monounsaturated fat lowers BP (Appel et al., 2005) . A few trials have tested the effects of periodic consumption of sugars, proteins, and fat in different probiotic products. The reduction in BP with milk products is well documented (Engberink et al., 2009) . Namely, dietary changes can lower BP and delay hypertension in non-hypertensive individuals (Appel, 2009) . Some intervention studies have also shown a BP-lowering effect of milk products and dairy proteins (AgerholmLarsen et al., 2000; Hata et al., 1996; Jauhiainen et al., 2005; Seppo et al., 2003; Sharafedtinov et al., 2013; Tuomilehto et al., 2004) . The result of the present comparative study is in accordance with those of a previous study finding that the most notable shifts with TENSIA were in diastolic BP values (Mikelsaar et al., 2012) . In obese patients on a hypocaloric diet and antihypertensive treatment, the extent of change of morning diastolic BP was closely associated with colonisation of molecularly detected probiotic L. plantarum TENSIA (Sharafedtinov et al., 2013) .
In our study, the BP-lowering effect among cheese consumers was also found in the placebo period, possibly the effect of starter and nonstarter lactobacilli of the Edam-type cheese. Milk-derived biologically active peptides and other substances affecting BP are present in cheese, including Edam, and produced by starter microbes, adventitious microflora, or rennet used during cheese production (Bütikofer et al., 2008; Gupta et al., 2013; Korhonen and Pihlanto, 2006; Sieber et al., 2010) . Similarly, the absence of clear differences in systolic BP reduction between probiotic and ordinary milk products may arise from the fact that milk compounds were present equally in probiotic and control products.
The consumption of either probiotic cheese or yoghurt for three weeks in this study did not depend on or influence BMI values or the level of plasma glucose, lipid profile, or inflammatory markers of blood despite the different carbohydrate, protein, and lipid content. Although, a low reduction of BMI was detected during the placebo intake in probiotic yoghurt trial. It may be due to the placebo effect or some carry-over effect. A previous study in healthy volunteers involving probiotic cheese containing TENSIA did not show changes in BMI values (Songisepp et al., 2012a) , either. However, in patients with metabolic syndrome, probiotic cheese with TENSIA caused a significant reduction in body water accompanied by decreased BMI (Sharafedtinov et al., 2013) .
In our intervention study with healthy adults, we identified a difference at baseline in BMI indices and BP values. This result showed that the diastolic BP-lowering effect with both dairy products containing L. plantarum TENSIA was relevant even in the general population with a large range of baseline values of BP. Recently, the BMI for the healthy population has been lowered to <24 kg/m 2 or less. According to the National Heart, Lung and Blood Institute, heart disease, diabetes, and high BP are all linked to being overweight (NIH, 2004) . Thus, in the general population, adults consider themselves healthy, but there is a large range of normality both for BMI and BP. It is important to know if functional food containing probiotics can positively influence borderline levels of prehypertension or reduce BP values. Evidence of a link between cheese consumption and vascular disease gives a lowered overall estimate of risk from cheese (Ciccarone et al., 2003; Lockheart et al., 2007) . In a wide-ranging review of studies of cheese consumption, Tholstrup found 'no convincing evidence of harm' and wrote on the 'neutral' effect of cheese on coronary heart disease (Tholstrup, 2006) . No risk was demonstrated by Elwood et al. (2007) reporting the results of a meta-analysis of cross-sectional studies of milk and/or dairy consumption and metabolic syndrome.
The only effect of probiotic L. plantarum TENSIA on blood biomarkers was found in yoghurt consumers in whom LDL-cholesterol was significantly lowered in both the probiotic and placebo treatment periods, possibly because of a carryover effect of probiotic yoghurt. A meta-analysis of 13 probiotic studies indicated that a diet rich in probiotics decreases total cholesterol and LDLcholesterol concentration in plasma for participants with high, borderline-high, and normal cholesterol levels (Guo et al., 2011) .
The limitations of the study were a possibly too short washout period after probiotic product consumption in both trials and a possible resulting carry-over effect that could have induced the BP reduction in the placebo period. In conclusion, our study showed that three-week consumption of probiotic L. plantarum TENSIA either in cheese or yoghurt lowered diastolic BP regardless of food matrix or different baseline values of BP and BMI, confirming the impact of functional properties of the probiotic strain in decreasing cardiovascular disease risk.
